Sign in
CompletedPhase 2

The Efficacy and Safety of Tofacitinib in Patients With Glucocorticoid Resistant ICIs-related Myocarditis

Key facts

Who runs it
Shanghai Zhongshan Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
25 people enrolled
Started
10 Apr 2024
Ended
16 Dec 2025
Type of study
Interventional
Treatments tested
  • Tofacitinib 5 MG BID
Record updated
26 October 2026

Who can take part

Age
18 years to 85 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Age ≥ 18 years old
  • Patients treated with ICI immunotherapy (monotherapy or combination), including anti-PD1, anti-PDL1, anti-CTLA4; and including any type of cancer (even those in which ICI is not currently approved by regulatory)
  • Definite, probable or possible ICI-induced myocarditis according to the diagnostic criteria of the most recent expert consensus recommendations (e.g27, to be updated with any new recommendations to be published)
  • corticosteroid-resistant ICI-myocarditis: Corticosteroid-resistant ICI-myocarditis is defined by the absence of decrease in troponin levels or the appearance/persistence of severity criteria despite receiving prednisone dose ≥0.5 mg/kg/day for ≥2 days
  • Signature of informed consent before any trial procedure from the patient or legal representative or the close relative
  • Patients covered by social security regimen (excepting AME)
  • Withhold of ICI

Who cannot take part

  • Being treated with tofacitinib within 3 months prior to inclusion Known hypersensitivity to abatacept or belatacept
  • Being treated with anti-thymoglobulin, or alemtuzumab within 6 weeks of the first scheduled dose of abatacept
  • Untreated and/or uncontrolled bacterial, fungal, or viral infection Pregnancy, breast-feeding or planning to become pregnant during the study period
  • For women of childbearing age, lack of effective contraception throughout the duration of participation in the study
  • Patient participating to another interventional study (RIPH 1 only) People under legal protection measure (tutorship, curatorship or safeguard measures)

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The efficacy and safety of Tofacitinib in patients with glucocorticoid resistant ICIs-related myocarditis: a single-arm, prospective, phase 2 trial

The group in the trial

  • TofacitinibTreatment being tested

    Tofacitinib in patients with glucocorticoid resistant ICIs-related myocarditis

    Treatment: Tofacitinib 5 MG BID

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Efficacy and Safety of Tofacitinib in Patients With Glucocorticoid Resistant ICIs-related Myocarditis: a Single-arm, Prospective, Phase 2 Trial
Record updated
26 October 2026